Choosing the Right CDMO for Long-Term Stability

The best-fit solution for your endeavor - Rentschler Development Services At Rentschler Biopharma, we are committed to being your strategic partner, providing not just solutions but also expert support that empowers your success and contribution to the treatment of serious and rare diseases. We recognize the importance of providing our clients with the best-fit solution to realizing their ideas and projects. Our Rentschler Development Services Program is a comprehensive framework aimed at tailoring development projects to clients’ particular needs and project stages. Our goal is to empower our clients by offering a range of tailored services. Whether you’re a startup or an established player, we understand that one size does not fit all. With the Development Services Program, you can choose from three different options: Velocity, Flexibility, and Liberty. Click to discover more Velocity Velocity is our fast-track service offering for clients who must be fast. With our fixed timelines, fixed prices and standardized processes , we reliably deliver released Drug Substance for your clinical Phase I/II project on-time. Click to discover more Flexibility Sometimes our clients require flexibility due to shifting priorities, unforeseen challenges, or changing market dynamics. Flexibility provides you with customized timelines and ensures that you can pivot, when necessary, without compromising quality independent of the clinical phase . Click to discover more Liberty For our clients who thrive on experimentation and innovation, Liberty offers you standalone activities and work packages to test hypotheses, fill a specific gap in your portfolio, iterate rapidly, and stay ahead of the wave . Click to discover more Interested? Then get in touch with our Business Development team at BIO International Convention or contact us via our website . | In this video interview, Dr. Patrick Meyer, our Global Head of Business Development at Rentschler Biopharma, outlines the deciding factors biotechs should consider when selecting a contract development and manufacturing organization (CDMO) partner. Discover what biotech companies should prioritize when evaluating a CDMO partnership. Patrick emphasizes that the decision carries long-term consequences given projects typically span many years. Key criteria discussed include transparent communication, accurate timelines, and a proven track record of guiding complex molecules through to commercialization. Also, he addresses the importance of technical expertise and supply chain reliability, noting that not all CDMOs are equipped to handle challenging molecules from the outset. Company stability, organizational size, and the depth of client engagement can factor into a biotech's selection process. Find out how we make your vision a success to commercialization and beyond. Together.